IGFBP-3高效可溶表达、纯化及生物学活性初步研究

克隆胰岛素样生长因子结合蛋白3(IGFBP-3)的cDNA片段,构建原核表达载体pET-DsBA-IGFBP3。将该重组质粒转化大肠杆菌BL21(DE3)plysS中,诱导表达IGFBP-3融合蛋白(简称D-IGFBP3)。经检测融合蛋白主要以可溶形式表达。表达产物用His亲和层析柱纯化,获得了纯度超过95%的重组IGFBP-3融合蛋白。Western-blot结果表明在相应分子量处有一条特异性条带。细胞活性研究显示它对MCF-7细胞生长具有一定的抑制作用,且在体外具有与IGF-I结合的活性。     

截短型人胰岛素样生长因子-Ⅰ 在大肠杆菌中的表达、纯化和鉴定

利用PCR、删除突变和基因重组技术构建了N端缺失3个氨基酸的人胰岛素样生长因子-[des(1-3)IGF-]的表达载体pExSec/IGF,在大肠杆菌蛋白酶缺陷株BL21(DE3)中,通过用IPTG于超常规的12℃低温诱导16h,des(1-3)IGF-获得了可溶性表达。表达水平达到可溶性细菌总蛋白约15%。经超滤和SephadexG-50凝胶过滤,des(1-3)IGF-纯度分别达到49%和82%,且表现出明显的免疫学活性和刺激Balb3T3细胞增殖的生物学活性。     

人肾小球系膜细胞纤溶酶原激活物抑制物cDNA克隆和高效表达

利用逆转录 聚合酶链式反应 (RT- PCR)方法 ,从中国正常人肾小球系膜细胞总RNA中扩增出人纤溶酶原激活物抑制物 (PAI 1 )基因cDNA编码区序列 ,并定向亚克隆至pUC1 9质粒 ,克隆的PAI -1cDNA去除了信号肽核苷酸序列并加入新的起始密码ATG ,编码区序列与文献报道的人内皮细胞PAI -1cDNA序列完全相同 .将PAI -1cDNA定向亚克隆至原核表达质粒 pBV2 2 0 ,构建了重组PAI -1基因表达质粒pBV2 2 0 PAI -1 ,在大肠杆菌中得到了高效表达 ,重组PAI -1蛋白表达占菌体总蛋白 45 % .Westernblotting检测 ,在分子量约为 43.0ku处出现一特异性蛋白质条带 .对形成包涵体的表达产物进行变复性处理及FPLC纯化 ,获得纯度 97%以上的潜伏态重组PAI -1 .经 4mol/L盐酸胍激活后 ,重组PAI- 1具有与天然PAI- 1同样的生物学活性 ,对尿激酶型纤溶酶原激活物 (u- PA)具有显著抑制活性 .     

草鱼胰岛素样生长因子-Ⅰ基因在大肠杆菌中的表达

 为构建草鱼 (Ctenopharyngodonidellus )胰岛素样生长因子 Ⅰ (IGF Ⅰ )大肠杆菌表达质粒 ,对已克隆到的草鱼IGF Ⅰ基因进行改造 .改造后的基因去除了原cDNA的信号肽和E区序列 ,并在基因的两端分别加入起始密码子和终止密码子 .将改造后的编码草鱼IGF Ⅰ成熟肽基因亚克隆到pBV 2 2 0中 ,构建成表达质粒pBVgIGF7.转化大肠杆菌 (Escherichiacoli)进行表达 .SDS PAGE显示 ,含重组表达质粒的菌株经热诱导后表达出一约 7 5kD的特异蛋白 .表达量占菌体总蛋白的2 0 0 3% ,表达产物主要以包涵体形式存在 .重组蛋白经纯化和复性后 ,采用MTT法测定其对草鱼吻端成纤维细胞PSF和草鱼卵巢细胞CO的促增殖作用 .结果表明 ,所获得的重组草鱼IGF Ⅰ具有生物活性     

基于蛋白质结构预测的胰岛素样生长因子-1的制备及活性分析北大核心CSCD

为了更经济高效地制备胰岛素样生长因子-1 (insulin-like growth factor-1, IGF-1),本研究采用计算机模拟技术对3种IGF-1融合蛋白进行蛋白质结构预测与分子对接,筛选出酶切最适配的IGF-1融合蛋白表达形式。利用基因工程技术构建并鉴定了IGF-1融合蛋白原核表达载体,并转化大肠杆菌Origami B(DE3)菌株,获得重组子;经异丙基-β-D-硫代吡喃半乳糖苷(isopropyl-β-D-1-thiogalactopyranoside, IPTG)诱导表达后,对菌体的破菌上清进行亲和层析、脱盐、凝血酶酶切及酶切产物亲和层析纯化得到目的蛋白;通过3T3细胞增殖法建立活性评价体系并对获得的IGF-1进行活性测定。结果显示,构建的IGF-1融合蛋白原核表达载体序列正确,获得的重组子在25℃、0.05 mmol/L IPTG诱导16 h时融合蛋白为可溶性表达,经初步纯化、凝血酶酶切、再次纯化后可获得纯度大于90%的IGF-1目的蛋白,在建立的活性评价体系下测得制备的IGF-1比活为2.47×10^(5)U/mg,与市售标准品接近。本研究建立了一条用于制备IGF-1的完整工艺路线,为IGF-1药物的研制及工业化生产奠定基础。     

肿瘤坏死因子相关的凋亡诱导配体(TRAIL)cDNA的克隆、表达和活性测定

肿瘤坏死因子相关的凋亡诱导配体 (TRAIL)能选择性诱导肿瘤细胞凋亡 .为利用基因工程技术获得重组TRAIL蛋白可溶性片段 (sTRAIL) ,设计 1对引物 .利用PCR技术特异性扩增出sTRAIL的cDNA ,克隆于质粒pGEM 3Zf( )的EcoRⅠ和PstⅠ位点 .经测序证明序列正确后克隆于表达质粒pBV2 2 0的EcoRⅠ和PstⅠ位点 ,转化大肠杆菌DH5α .转化菌株经温度诱导 ,SDS PAGE检测和Western印迹鉴定 ,获得重组sTRAIL的高水平非融合表达菌株 .表达量占菌体总蛋白的 2 0 % .对其表达产物进行了初步纯化 ,SDS PAGE结果显示纯度可达 90 %以上 .用L92 9细胞测定其生物学活性表明 ,重组蛋白在体外能明显诱导肿瘤细胞凋亡     

人谷胱甘肽硫转移酶A1在乳酸乳球菌中的表达及活性研究

用RTPCR技术从人肝总RNA中分离扩增了人谷胱甘肽硫转移酶A1基因的cDNA序列,克隆至大肠杆菌表达质粒pET23b,采用蛋白表达筛查法及DNA测序证明该cDNA序列完全正确。重组质粒pET23bhgst转化大肠杆菌BL21(DE3),经IPTG诱导获得高效表达的可溶性hGSTA1产物,其表达量约为大肠杆菌可溶性总蛋白的40%。将hGSTA1cDNA亚克隆至乳酸乳球菌表达载体pMG36e,电穿孔法转化乳酸乳球菌MG1363获得hGSTA1乳酸乳球菌表达株。SDSPAGE及Western杂交分析表明该菌株表达预期大小的hGSTA1融合蛋白,经谷胱甘肽琼脂糖亲和层析纯化获得的hGSTA1蛋白具有较高的谷胱甘肽硫转移酶活性。具hGSTA1酶活性的乳酸乳球菌工程菌可望应用于研制防癌保健乳制品。     

水貂IGF-Ⅰ基因的克隆、序列分析及原核表达分析

获得水貂IGF-Ⅰ基因的cDNA序列,实现IGF-Ⅰ基因在大肠杆菌中的融合表达。利用RT-PCR技术从水貂肝脏组织扩增出水貂胰岛素样生长因子Ⅰ（IGF-Ⅰ）的编码区序列。此序列编码153个氨基酸的前体蛋白质。同源性分析表明IGF-Ⅰ的核苷酸和氨基酸序列与已报道的金丝猴、小熊猫、大熊猫、东北虎、马等哺乳动物的序列高度同源（＞90%）。对位比较发现水貂的信号肽序列具有氨基酸特异性,这些氨基酸是否影响水貂IGF-Ⅰ分子的构型、进而影响功能则需要进一步的研究。将构建的重组表达载体pGEX-6P-1-IGF-Ⅰ转入大肠杆菌BL21进行原核表达,得到高效融合表达,融合蛋白分子量约为34 KD。Western-blotting杂交证实了表达蛋白的抗原活性。本研究成功克隆、表达了水貂IGF-Ⅰ基因,分析和预测了其结构和功能,为进一步的生物活性研究打下基础。     

人ob基因克隆及其亚细胞定位的研究

目的:旨在克隆人肥胖(obese,ob)基因的全长cDNA序列,与EGFP重组构建融合蛋白表达载体,并分析其亚细胞水平的定位.方法:提取人脂肪细胞总RNA,采用RT-PCR方法扩增出人ob基因cDNA,并克隆至真核表达载体pEGFP-CI,重组质粒转染NIH-3T3细胞,荧光显微镜分析EGFP-ob融合蛋白的亚细胞定位.结果:克隆的ob基因cDNA为501bp,共编码167个氨基酸,与GenBank公布的人ob基因序列一致,荧光显微镜分析表明,重组的EGFP-ob融合蛋白主要分布于NIT-3T3的细胞质中.结论:成功克隆了人OB基因的cDNA序列,构建人OB基因的真核表达载体pEGFP-CI-ob,融合蛋白EGFP-ob定位于NIH-3T3细胞质中.     

剪接因子1N端1-320氨基酸片段的原核表达及纯化

目的:通过扩增剪接因子1(SF1)的N端1-320氨基酸(aa)片段对应的cDNA,构建His融合蛋白原核表达质粒pET-28a(+)/SF1(1-320aa),在大肠杆菌中诱导表达并进行亲和纯化。方法:PCR扩增SF1的1-320 aa片段对应的cDNA,扩增产物和载体pET-28a(+)经酶切回收,连接载体和目的片段,获得重组质粒,转化大肠杆菌DH5α,挑取克隆、酶切鉴定、测序,将测序正确的重组质粒转化大肠杆菌BL21(DE3),IPTG诱导表达,SDS-PAGE和West-ern印迹分析蛋白表达情况,亲和纯化His-SF1(1-320aa)。结果:SF1片段以正确的读框插入pET-28a(+),IPTG可以诱导大肠杆菌表达重组蛋白,SDS-PAGE和Western印迹证实得到相对分子质量约为40×103的蛋白,亲和纯化得到高纯度蛋白质。结论:构建了His融合蛋白原核表达质粒pET-28a(+)/SF1(1-320aa),并获得His-SF1(1-320aa)融合蛋白,为进一步研究SF1和U2AF65之间的相互作用及对剪接体形成的影响提供了基础。     

miR-223 contributes to the AGE-promoted apoptosis via down-regulating insulin-like growth factor 1 receptor in osteoblasts

Advanced glycation end products (AGEs) have been confirmed to induce bone quality deterioration in diabetes mellitus (DM), and to associate with abnormal expression of miRNAs in DM patients or in vitro. Recently, miRNAs have been recognized to mediate the onset or progression of DM. In the present study, we investigated the regulation on miR-223 level by AGE-BSA treatment in osteoblast-like MC3T3-E1 cells, with real-time quantitative PCR assay. And then we examined the inhibition of insulin-like growth factor 1 receptor (IGF-1R) expression by miR-223, via targeting of the 3′ UTR of IGF-1R with real-time quantitative PCR, western blotting and luciferase reporter assay. Then we explored the regulation of miR-223 and IGF-1R levels, via the lentivirus-mediated miR-223 inhibition and IGF-1R overexpression in the AGE-BSA-induced apoptosis in MC3T3-E1 cells. It was demonstrated that AGE-BSA treatment with more than 100 μg/ml significantly up-regulated miR-223 level, whereas down-regulated IGF-1R level in MC3T3-E1 cells. And the up-regulated miR-223 down-regulated IGF-1R expression in both mRNA and protein levels, via targeting the 3′ UTR of IGF-1R. Moreover, though the AGE-BSA treatment promoted apoptosis in MC3T3-E1 cells, the IGF-1R overexpression or the miR-223 inhibition significantly attenuated the AGE-BSA-promoted apoptosis in MC3T3-E1 cells. In summary, our study recognized the promotion of miR-223 level by AGE-BSA treatment in osteoblast-like MC3T3-E1 cells. The promoted miR-223 targeted IGF-1R and mediated the AGE-BSA-induced apoptosis in MC3T3-E1 cells. It implies that miR-223 might be an effective therapeutic target to antagonize the AGE-induced damage to osteoblasts in DM.     

Expression,purification, and characterization of a biologically active bovine enterokinase catalytic subunit in Escherichia coli

Enterokinase (EC 3.4.21.9) is a serine proteinase in the duodenum that exhibits specificity for the sequence (Asp)(4)-Lys. It converts trypsinogen to trypsin. Its high specificity for the recognition site makes enterokinase (EK) a useful tool for in vitro cleavage of fusion proteins. cDNA encoding the catalytic chain of Chinese bovine enterokinase was cloned and its encoding amino acid sequence is identical to the previously reported sequence although there are two one-base mutations which do not change the encoded amino acid. The EK catalytic subunit cDNA was cloned into plasmid pET32a, and fused downstream to the fusion partner thioredoxin (Trx) and the following DDDDK enterokinase recognition sequence. The recombinant bovine enterokinase catalytic subunit was expressed in Escherichia coli BL21(DE3), and most products existed in soluble form. After an in vivo autocatalytic cleavage of the recombinant Trx-EK catalytic domain fusion protein, intact, biologically active EK catalytic subunit was released from the fusion protein. The recombinant intact EK catalytic subunit was purified to homogeneity with a specific activity of 720 AUs/mg protein through ammonium sulfate precipitation, DEAE chromatography, and gel filtration. The purified intact EK catalytic subunit has a K(m) of 0.17 mM, and K(cat) is 20.8s(-1). From 100 ml flask culture, 4.3 mg pure active EK catalytic subunits were obtained.     

人组织性纤溶酶原激活物衍生物在大肠杆菌硫氧化还原蛋白融合表达系统中的表达

目的:克隆含tPA中355个氨基酸密码子(1-3和176-527氨基酸)的cDNA序列(tPA355),将其在大肠杆菌融合蛋白表达系统中表达,并在体外复性使其具有激活纤溶酶原的生物活性。方法:采用RT-PCR技术从人黑色素瘤细胞Bowes中克隆出tPA355cDNA,然后在pET32a(+)BL21(DE3)大肠杆菌表达系统中表达,将表达出的融合蛋白Trx-tPA355(Thioredoxin,Trx)包涵体在体外进行变性、复性和纯化以使其具有激活纤溶酶原的生物活性。结果:测序结果表明本研究克隆的编码tPA中355个氨基酸密码子的cDNA序列与美国专利(公开号:5,587,159)中对应的序列完全一致,将其在pET32a(+)/BL21(DE3)大肠杆菌表达系统中表达可获得稳定表达的融合蛋白Trx-tPA355包涵体,该包涵体占菌体总蛋白的30%左右,此融合蛋白经变性、复性后具有激活纤溶酶原的生物活性。结论:含tPA中355个氨基酸密码子(1-3和176-527氨基酸)的cDNA在大肠杆菌Trx融合蛋白表达系统中可获得稳定表达,表达的融合蛋白产物在体外经变性、复性后具有激活纤溶酶原的生物活性。     

力生长因子及其E肽对成骨细胞分化的影响

力生长因子(mechano growth factor,MGF)是新近发现的一种生长因子,由Igf-1基因剪接变异产生,拉伸刺激会促使成骨细胞表达力生长因子.比较分析了MGF及其羧基端E肽(MGF-Ct24E)对成骨细胞前体细胞MC3T3-E1分化的影响.结果显示:MGF和MGF-Ct24E具有显著激活胞外信号调节激酶1/2(Erk1/2)的作用,并降低了成骨细胞碱性磷酸酶、Ⅰ型胶原的表达,促进了骨桥蛋白(OPN)的表达,减少了核心绑定因子(corebinding factor1,Cbfα-1)的核转运量,对成骨细胞的分化具有延迟效应,这种效应通过抑制剂PD98059抑制Erk1/2的活化得到逆转;MGF还能显著激活磷脂酰肌醇3-激酶信号通路中的蛋白激酶B(Akt),该活化作用对成骨细胞分化是必需的,钙沉积分析显示长期培养下的细胞MGF促进了矿化节结的形成.这些结果说明,MGF-Ct24E对成骨细胞的分化具有抑制作用,这种作用与Erk1/2的活化有关,MGF因为包含E肽和IGF-1部分,能分别激活Erk1/2和Akt,因此对成骨细胞分化表现出双重效用,在成骨细胞分化早期,具有一定的延迟效应,而在分化晚期对成骨...     

重组类胰岛素样生长因子-Ⅰ的纯化与复性

目的 获得高纯度和高活性的胰岛素样生长因子（Insulin-like growth factor, IGF-1）;方法 构建好的BL21大肠杆菌工程菌经IPTG诱导,以融合一段截短型半乳糖苷酶及His-tag形式表达IGF-1融合蛋白(约15,000Da),超声破碎,提取包涵体经镍柱亲和层析后, 用羟氨切割纯化的融合蛋白,纯化后的蛋白质在小分子保护剂及GSH/GSSG的存在下复性。结果 经Ni2＋柱亲和层析, IGF-1纯度达90％以上,复性后得到有较高生物活性的IGF-1。结论 IGF-1发酵及纯化和复性方法的建立为大量生产IGF-1打下了基础。     

3-D in vitro model of early skeletal muscle development

An understanding of the mechanical and mechano-molecular responses that occur during the differentiation of mouse C2C12 [corrected] myoblasts in 3-D culture is critical for understanding growth, which is important for progress towards producing a tissue-engineered muscle construct. We have established the main differences in force generation between skeletal myoblasts, dermal fibroblasts, and smooth muscle cells in a 3-D culture model in which cells contract a collagen gel construct. This model was developed to provide a reproducible 3-D muscle organoid in which differences in force generation could be measured, as the skeletal myoblasts fused to form myotubes within a collagen gel. Maintenance of the 3-D culture under sustained uni-axial tension, was found to promote fusion of myoblasts to form aligned multi-nucleate myotubes. Gene expression of both Insulin Like Growth Factor (IGF-1 Ea) and an isoform of IGF-1 Ea, Mechano-growth factor (IGF-1 Eb, also termed MGF), was monitored in this differentiating collagen construct over the time course of fusion and maturation (0-7 days). This identified a transient surge in both IGF-1 and MGF expression on day 3 of the developing construct. This peak of IGF-1 and MGF expression, just prior to differentiation, was consistent with the idea that IGF-1 stimulates differentiation through a Myogenin pathway [Florini et al., 1991: Mol. Endocrinol. 5:718-724]. MGF gene expression was increased 77-fold on day 3, compared to a 36-fold increase with IGF-1 on day 3. This indicates an important role for MGF in either differentiation or, more likely, a response to mechanical or tensional cues.     

人IGF-1在大肠杆菌中的可溶表达和纯化

目的:在大肠杆菌中的可溶表达和纯化人胰岛素样生长因子1(hIGF-1)。方法:根据hIGF-1的氨基酸序列和大肠杆菌密码子偏爱性,利用重叠延伸PCR的方法合成hIGF-1DNA序列,构建表达载体,在大肠杆菌OrigamiB(DE3)中与硫氧还蛋白TrxA融合表达,并通过盐析和镍柱亲合层析进行纯化。结果:SDS-PAGE分析显示,重组融合蛋白以可溶形式存在,分子量约为28kDa,占上清总蛋白的50%以上。经盐析和镍柱亲合层析进行纯化,目标蛋白纯度可达到90%左右。结论:复合干扰素在大肠杆菌中的高效可溶表达。     

MutL融合蛋白的高效表达及其伴侣功能研究(英文)

DNA错配修复蛋白MutL和其它的修复蛋白相互作用来共同完成大肠杆菌甲基介导的错配修复过程 .为研究修复蛋白MutL的体外生物功能构建了融合蛋白Trx His6 Linkerpeptide MutL(THLL)的表达载体并使其高效表达及易于纯化 .mutL基因片段是以E .coliK 12基因组为模板经PCR扩增获得 ,并通过基因的体外拼接成功构建了融合蛋白THLL表达载体pET32a linkerpeptide mutL .重组菌株E .coliAD4 94 (DE3) pET32a linkerpeptide mutL经过IPTG的诱导表达了融合蛋白THLL .收集菌体细胞、超声波破碎后离心取上清进行SDS PAGE分析 ,结果表明有一与预期分子量(84kD)相应的诱导表达条带出现 ,其表达量约占全细胞蛋白的 30 %且以可溶形式存在 .利用固定化金属离子 (Ni2 +)配体亲和层析柱纯化融合蛋白THLL ,其纯度达到 90 % .通过非变性凝胶电泳分析 ,对融合蛋白THLL在DNA错配修复过程中的分子伴侣生物功能进行了系统研究 .结果表明 ,THLL能增加融合蛋白Trx His6 Linkerpeptide MutS (THLS)与含有错配碱基DNA双链的结合 ,但受ATP的浓度变化影响很大     

Application of immobilized bovine enterokinase in repetitive fusion protein cleavage for the production of mucin 1

Bovine enterokinase is a serine protease that catalyzes the hydrolysis of peptide bonds and plays a key role in mammalian metabolism. Because of its high specificity towards the amino acid sequence (Asp)₄-Lys, enterokinase is a potential tool for the cleavage of fusion proteins, which are gaining more importance in biopharmaceutical production. A candidate for adaptive cancer immunotherapy is mucin 1, which is produced recombinantly as a fusion protein in CHO cells. Here, we present the first repetitive application of immobilized enterokinase for the cleavage of the mucin fusion protein. The immobilization enables a facile biocatalytic process due to simplified separation of the biocatalyst and the target protein. Immobilized enterokinase was applied in a maximum of 18 repetitive reactions. The enzyme utilization (total turnover number) was increased significantly 419-fold compared to unbound enzyme by both immobilization and optimization of process conditions. Slight enzyme inactivation throughout the reaction cycles was observed, but was compensated by adjusting the process time accordingly. Thus, complete fusion protein cleavage was achieved. Furthermore, we obtained isolated mucin 1 with a purity of more than 90% by applying a simple and efficient purification process. The presented results demonstrate enterokinase to be an attractive tool for fusion protein cleavage.